AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02526173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dHACM Application
Description: 2x12 sheet of dHACM applied to the neurovascular bundle
Study NCT03516617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study NCT03516617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03492385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: 30 minute - 12 hour infusion
Study NCT03516617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03516617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT03516617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation
Study NCT03516617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03516617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01347307 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT for Benign Extradural Spine Tumors
Description: 14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
Study NCT01587872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fujinon EC-450BI5 double-balloon colonoscope
Description: Colonoscopy with the test instrument
Study NCT01539837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone 20mg
Description: 20mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
Study NCT01347307 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT for Vertebral/Paraspinal Metastases
Description: 12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
Study NCT00497276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placement of popliteal catheter
Description: Bolus naropin 7,5 mg/ml 30 ml; infusion bupivacaine 2,5 mg/ml 5-10 ml/h
Study NCT01752491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Intravenous infusion of high-dose ascorbate
Study NCT01539837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day
Study NCT01539837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone 30mg
Description: 30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
Study NCT01752491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral chemotherapeutic
Study NCT03492385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo
Study NCT03492385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo and Ticagerlor 180 mg 24 hours following MEDI2452 (PB2452) or Placebo
Study NCT00461955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous peripheral blood stem cell transplantation, ex vivo amplified
Description: autologous peripheral blood stem cell transplantation, ex vivo amplified
Study NCT01752491 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: External beam radiation therapy
Study NCT03897270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoacoustic Imaging
Description: Undergo photoacoustic imaging of the breast
Study NCT06637553 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adlay formula
Description: The extract will be administered at a dose of 20 grams dissolved in 200cc of hot water once daily
Study NCT06637553 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same weight as the adlay formula but did not include the active compound
Study NCT04072354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856 50mg
Description: SEP-363856 50mg tablet dosed once daily
Study NCT04072354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856 75mg
Description: SEP-363856 75mg tablet dosed once daily
Study NCT03084510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Edge™ Valve System
Description: • The Lotus Edge™ Valve System consisting of two main components:~* a bioprosthetic bovine pericardial aortic valve, and~* a delivery system Device sizes include 23 mm, 25 mm and 27 mm diameter.
Study NCT00595075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg tablet by mouth x 1 dose
Study NCT00595075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo identical in appearance to active experimental drug x 1 dose
Study NCT06542341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: decoLITE (TN2037)
Description: Red/Near infra red light therapy
Study NCT03060707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium Bromide
Description: Continuously infuse, or bolus administer rocuronium.
Study NCT03060707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Bromide
Description: Continuously infuse, or bolus administer rocuronium.
Study NCT04067622 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Exersides
Description: A novel arm restraint which permits arm mobility but prohibits hands from reaching oral/nasal endotracheal and feeding tubes or intravenous lines.
Study NCT02396927 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D HD laparoscopy
Description: Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
Study NCT04420182 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Care at Home
Description: Participants will have access to the VIRTUES platform for COVID-19 Virtual Care at Home
Study NCT00489359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed - Phase 1
Description: 500, 600, 700, 800, or 900 milligrams per square meter (mg/m\^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)
Study NCT00489359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin - Phase 1
Description: area under the concentration time curve (AUC) 5 or 6 mg/mL\*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)
Study NCT00489359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed - Phase 2
Description: Dose determined from Phase 1: 500 mg/m\^2, administered IV, every 21 days x 6 cycles
Study NCT00489359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin - Phase 2
Description: Dose determined from Phase 1: AUC 6 mg/mL\*min, administered IV, every 21 days x 6 cycles
Study NCT03656614 — intervention group
Intervention type: DRUG
Intervention: Sugammadex
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)
Study NCT03656614 — intervention group
Intervention type: DRUG
Intervention: Neostigmine
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 40 µg/kg (Neostigmine 40) Neostigmine 55 µg/kg (Neostigmine 55) Neostigmine 70 µg/kg (Neostigmine 70)~Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow.
Study NCT02396927 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 2D HD laparoscopy
Description: Placebo
Study NCT03656614 — intervention group
Intervention type: DRUG
Intervention: Saline 0.9%
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of saline 0.9%.
Study NCT04176705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Cream
Description: Both sites will have lidocaine 4% topical anesthetic cream (Ferndale Laboratories, Ferndale MI) applied as thin layer and left for 30-45 minutes to minimize discomfort applied before laser treatment.
Study NCT04176705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine Cream
Description: Both sites will have lidocaine 4% topical anesthetic cream (Ferndale Laboratories, Ferndale MI) applied as thin layer and left for 30-45 minutes to minimize discomfort applied before laser treatment.
Study NCT00515216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Study NCT00515216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT00515216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT01256060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: We are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.
Study NCT00842816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: 10 mg; administered once/day
Study NCT00842816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: 60 mg; administered once/day
Study NCT00842816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: 120 mg; administered once/day
Study NCT00842816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets to match ST101 tablets
Study NCT01086969 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)
Description: 0.5 mL, Intramuscular
Study NCT03721887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
Study NCT03721887 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
Study NCT01746654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P128-0.1 mg
Description: P-128 at 0.1 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
Study NCT01746654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P128-0.3 mg
Description: P-128 at 0.3 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
Study NCT01746654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P128-1.0 mg
Description: P-128 at 1.0 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; once in Part D.
Study NCT01746654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered to both nares once in part A, multiple times in Part B and Part C, Once in part D
Study NCT03998462 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: MBSR consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
Study NCT03998462 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Creative Education Care
Description: Creative Education Care consists of 6-10 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
Study NCT04176705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide Cream
Description: Triamcinolone acetonide cream (Bristol-Myers Squibb, Princeton, NJ) at a concentration of 20mg/ml will be applied immediately after treatment to both laser and no-laser sites - as this is often reported and there is some speculation that this may be part of the reason improvement is noted.
Study NCT04176705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triamcinolone Acetonide Cream
Description: Triamcinolone acetonide cream (Bristol-Myers Squibb, Princeton, NJ) at a concentration of 20mg/ml will be applied immediately after treatment to both laser and no-laser sites - as this is often reported and there is some speculation that this may be part of the reason improvement is noted.
Study NCT04176705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Ablative Laser
Description: Applied to only site that is randomized to laser intervention
Study NCT04072354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet dosed once daily
Study NCT01366222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: food concentrates: fruit, vegetable, fish oil and probiotics
Description: comparison the effect of food concentrate
Study NCT01366222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: food concentrates: fruit, vegetable, fish oil and probiotics
Description: comparison the effect of food concentrate
Study NCT01279538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bleselumab
Description: Intravenous (IV) infusion
Study NCT00718731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSI-136
Study NCT01362192 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 532 nm KTP Excel V Laser, manufactured by Cutera, Inc.
Description: The 532 nm KTP Excel V laser treatment parameters to be used in this study are as follows:~* Spot Size: 5 mm~* Fluence: 13-15 J/cm2~* Pulse Duration: 40 ms~* Epidermal contact-cooling: 5° Celsius
Study NCT00718731 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00456365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin
Description: Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)
Study NCT01468103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Iridectomy
Description: Surgical Iridectomy is now widely used in our clinical.
Study NCT01468103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Iridotomy
Description: alternative choice to surgical iridectomy
Study NCT01860781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Description: paliperidone palmitate 150mgeq(1 day), 100mgeq(8days), 75mg(monthly)
Study NCT01254903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SSRS)
Description: Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
Study NCT00456365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily
Study NCT01558505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEB
Description: paclitaxel-eluting balloon angioplasty
Study NCT04093349 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SPK-3006
Description: adeno-associated viral (AAV) vector
Study NCT01558505 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POBA
Description: conventional balloon angioplasty
Study NCT00091897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT00091897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab or placebo
Description: A fixed dose of Rituximab or placebo 1GM on Day 1 and 1GM on day 15 (+/- 2 days)
Study NCT03275831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PluroGel
Description: Surfactant based gel
Study NCT03275831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrasite gel
Description: Hydrogel
Study NCT02395328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Worker Home Visitation
Description: Primary services include biweekly home visits from Care Workers trained, mobilized and supported by Futures Families, a South African non-government organization working to support OVC in six townships within the greater Tshwane area (also known as Pretoria) of South Africa.
Study NCT02951819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: For induction therapy cycle 1 day 1 and day 2 doses of daratumumab will be 8 milligram/kilogram (mg/kg). Starting cycle 1 week 2 until the completion of week 8 of daratumumab patients will receive 16 mg/kg Intravenously (IV) weekly.~Starting week 9 until the completion of week 24 therapy daratumumab will be administered every other week at 16 mg/kg IV.~Starting week 25 and beyond for induction therapy daratumumab will be given once every 4 weeks.
Study NCT01279538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion
Study NCT01540344 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CRS
Description: complete macroscopic cytoreduction (CC-0/1)
Study NCT01821170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Patient will take treatment during two months
Study NCT01821170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cognitive remediation
Description: Patient will have 12 sessions during 6 to 8 weeks
Study NCT01821170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: supportive psychotherapy
Description: Patients will have 12 sessions during 6 to 8 weeks
Study NCT01540344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP
Study NCT01545739 — intervention group
Intervention type: DEVICE
Intervention: Evia/Entovis HF-T pacemaker for CRT therapy
Description: Implantation of CRT pacemaker and standard follow-ups at pre-hospital discharge, and after 1, 3 and 6 months
Study NCT01023061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Given PO
Study NCT01821170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological tests
Description: neuropsychological tests will assess attentional and executive performance
Study NCT01023061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study NCT01023061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Given via injection
Study NCT01023061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT01023061 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Undergo radiotherapy
Study NCT01023061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Given via injection
Study NCT03391115 — intervention group
Intervention type: BEHAVIORAL
Intervention: Storytelling Intervention for Patient Participants
Description: The storytelling intervention consists of an audio-recorded interview with each patient participant prompted the participant to share their story with questions such as: tell me about your illness, tell me how your illness has affected your emotions, relationships, and spirituality. The interview transcripts will be used to co-create a 1 page patient story using these criteria:1) written in the first person; 2) nonjudgmental; 3) captures the participant's voice; 4) accurately reflects content of the interview; and 5) non-labeling. Once the story has been approved by the participant, I will upload it to the EHR.